

# Breast Cancer Screening (BCS-E)

## New for 2026

### Removed

- Removed required exclusion for the combination of unilateral mastectomy with a bilateral modifier



**Yes!**  
Supplemental  
Data Accepted

## Definition

Percentage of members ages 40-74 who were recommended for routine breast cancer screening and had a mammogram screening completed on or by Oct. 1, 2 years prior to the measurement year through Dec. 31 of the measurement year.

Plans(s) affected	Quality program(s) affected	Collection and reporting method
<ul style="list-style-type: none"> <li>• Commercial</li> <li>• Exchange/Marketplace</li> <li>• Medicaid</li> <li>• Medicare</li> </ul>	<ul style="list-style-type: none"> <li>• CMS Star Ratings</li> <li>• CMS Quality Rating System</li> <li>• NCQA Health Plan Ratings</li> </ul>	<ul style="list-style-type: none"> <li>• Electronic Clinical Data Systems (ECDS) reporting</li> </ul>

## Codes

The following codes can be used to close HEDIS numerator gaps in care; they are not intended to be a directive of your billing practice.

Mammography	
<b>CPT®/CPT II</b>	77061, 77062, 77063, 77065, 77066, 77067
<b>LOINC</b>	103885-0, 103886-8, 103892-6, 103893-4, 103894-2, 24604-1, 24605-8, 24606-6, 24610-8, 26175-0, 26176-8, 26177-6, 26287-3, 26289-9, 26291-5, 26346-7, 26347-5, 26348-3, 26349-1, 26350-9, 26351-7, 36319-2, 36625-2, 36626-0, 36627-8, 36642-7, 36962-9, 37005-6, 37006-4, 37016-3, 37017-1, 37028-8, 37029-6, 37030-4, 37037-9, 37038-7, 37052-8, 37053-6, 37539-4, 37542-8, 37543-6, 37551-9, 37552-7, 37553-5, 37554-3, 37768-9, 37769-7, 37770-5, 37771-3, 37772-1, 37773-9, 37774-7, 37775-4, 38070-9, 38071-7, 38072-5, 38090-7, 38091-5, 38807-4, 38820-7, 38854-6, 38855-3, 42415-0, 42416-8, 46335-6, 46336-4, 46337-2, 46338-0, 46339-8, 46350-5, 46351-3, 46356-2, 46380-2, 48475-8, 48492-3, 69150-1, 69251-7, 69259-0, 72137-3, 72138-1, 72139-9, 72140-7, 72141-5, 72142-3, 86462-9, 86463-7, 91517-3, 91518-1, 91519-9, 91520-7, 91521-5, 91522-3

## Breast Cancer Screening (BCS-E) (cont.)

### Required exclusion(s)

Exclusion	Time frame
<ul style="list-style-type: none"> <li>Members in hospice or using hospice services</li> <li>Members who died</li> <li>Members receiving palliative care</li> </ul>	Any time during the measurement year
<p>Members 66 years of age and older as of Dec. 31 of the measurement year with frailty and advanced illness. Members must meet both frailty and advanced illness criteria to qualify as an exclusion:</p> <ul style="list-style-type: none"> <li>Frailty: At least 2 diagnoses of frailty on different dates of service during the measurement year. Do not include claims where the frailty diagnosis was from an independent lab (POS 81).</li> <li>Advanced Illness: Indicated by 1 of the following:               <ul style="list-style-type: none"> <li>At least 2 diagnoses of advanced illness on different dates of service during the measurement year or year prior. Do not include claims where the advanced illness diagnosis was from an independent lab (POS 81).</li> <li>Dispensed dementia medication Donepezil, Donepezil-Memantine, Galantamine, Rivastigmine or Memantine</li> </ul> </li> </ul>	<p><b>Frailty</b> diagnoses must be in the measurement year and on different dates of service</p> <p><b>Advanced illness</b> diagnosis must be in the measurement year or year prior to the measurement year</p>
<p>Medicare members ages 66 and older as of Dec. 31 of the measurement year who are either:</p> <ul style="list-style-type: none"> <li>Enrolled in an Institutional Special Needs Plan (I-SNP)</li> <li>Living long term in an institution</li> </ul>	Any time during the measurement year

## Breast Cancer Screening (BCS-E) (cont.)

Exclusion	Time frame
<p>Bilateral mastectomy</p> <ul style="list-style-type: none"> <li>• History of bilateral mastectomy</li> <li>• Any combination of the following that indicate a mastectomy on both the left and right side:               <ul style="list-style-type: none"> <li>- Absence of the left and right breast</li> <li>- Left unilateral mastectomy</li> <li>- Right unilateral mastectomy</li> </ul> </li> <li>• Members who had gender-affirming chest surgery with a diagnosis of gender dysphoria</li> </ul>	<p>Any time in a member's history through Dec. 31 of the measurement year</p>



### Important notes

	Test, service or procedure to close care opportunity	Medical record detail including, but not limited to
<ul style="list-style-type: none"> <li>• This measure does not include biopsies, breast ultrasounds or MRIs</li> <li>• If documenting a mammogram in a member's history, please include the month and year. The result is not required.</li> </ul>	<p>Mammogram - all types and methods including screening, diagnostic, film, digital or digital breast tomosynthesis</p>	<ul style="list-style-type: none"> <li>• Consultation reports</li> <li>• Diagnostic reports</li> <li>• Health history and physical</li> </ul>

## Breast Cancer Screening (BCS-E) (cont.)

### Tips and best practices to help close this care opportunity

- **Always include a date of service – year and month is acceptable – when documenting a mammogram reported by a member**
- Thermography for any indication (including breast lesions which were excluded from Medicare coverage on July 20, 1984) is excluded from Medicare coverage
- As an ECDS measure, it's important to submit the appropriate ICD-10 Diagnosis code that reflects a member's history of bilateral mastectomy, Z90.13
  - If a member is new to the care provider and the diagnosis is discovered during the history and physical, the code should be submitted with the initial visit claim
  - If a member isn't new to the care provider, but the member's chart has a documented history of the diagnosis, the ICD-10 Diagnosis code should be submitted on any visit claim
- Breast cancer screening or mastectomy codes can be accepted as supplemental data, reducing the need for some chart review. Please contact your UnitedHealthcare representative to discuss clinical data exchange opportunities.
- Member refusal will not make them ineligible for this measure

## Breast Cancer Screening (BCS-E) (cont.)

### Additional measure resources

<ul style="list-style-type: none"> <li>• <a href="#">ACS NBCRT Risk Assessment Toolkit – NBCRT</a></li> </ul>	<p>The American Cancer Society National Breast Cancer Roundtable (ACS NBCRT) assembled this digital toolkit to support practices and providers in conducting breast cancer risk assessments. Breast cancer risk assessment helps identify individuals at higher risk for breast cancer to enable personalized screening, prevention and early detection strategies. This toolkit presents evidence-based breast cancer risk assessment tools and provides guidance for providers on their effective use.</p>
<ul style="list-style-type: none"> <li>• <a href="#">Recommendation: Breast Cancer: Screening   United States Preventive Services Taskforce</a></li> </ul>	<p>U.S. Preventive Services Task Force recommendations for biennial screening for women aged 40-74 years.</p>
<ul style="list-style-type: none"> <li>• <a href="#">Safety Considerations for COVID-19 Vaccines   COVID-19   CDC</a></li> </ul>	<p>Per the CDC, lymphadenopathy may occur 4-6 weeks after the COVID-19 vaccination. Please encourage your patients to wait the appropriate amount of time before scheduling their mammogram or complete the mammogram before receiving the COVID-19 vaccine, to account for lymphadenopathy. This will help prevent the vaccine impacting screening results.</p>